VioQuest Pharmaceuticals, Inc. (VOQP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2007 | 5.84 Million USD | 95.56% |
| 2006 | 2.98 Million USD | 46.43% |
| 2005 | 2.04 Million USD | 87.71% |
| 2004 | 1.08 Million USD | 42.92% |
| 2003 | 760.52 Thousand USD | 475.16% |
| 2002 | 132.22 Thousand USD | -48.4% |
| 2001 | 256.23 Thousand USD | 61.85% |
| 2000 | 158.31 Thousand USD | 0.01% |
| 1999 | 158.3 Thousand USD | 17.21% |
| 1998 | 135.05 Thousand USD | -3.99% |
| 1997 | 140.67 Thousand USD | -17.55% |
| 1996 | 170.62 Thousand USD | -3.65% |
| 1995 | 177.08 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2008 Q1 | 7.38 Million USD | 26.37% |
| 2008 Q2 | 6.84 Million USD | -7.25% |
| 2007 Q2 | 5.63 Million USD | 78.39% |
| 2007 Q3 | 5.59 Million USD | -0.75% |
| 2007 Q4 | 5.84 Million USD | 4.5% |
| 2007 Q1 | 3.15 Million USD | 5.7% |
| 2007 FY | 5.84 Million USD | 95.56% |
| 2006 FY | 2.98 Million USD | 46.43% |
| 2006 Q1 | 1.27 Million USD | -37.27% |
| 2006 Q2 | 1.94 Million USD | 52.22% |
| 2006 Q3 | 2.12 Million USD | 9.2% |
| 2006 Q4 | 2.98 Million USD | 40.44% |
| 2005 Q4 | 2.04 Million USD | -12.97% |
| 2005 Q1 | 1.19 Million USD | 9.49% |
| 2005 Q2 | 1.79 Million USD | 50.93% |
| 2005 FY | 2.04 Million USD | 87.71% |
| 2005 Q3 | 2.34 Million USD | 30.52% |
| 2004 Q3 | 608.83 Thousand USD | -20.82% |
| 2004 Q1 | 628.62 Thousand USD | -17.34% |
| 2004 Q4 | 1.08 Million USD | 78.53% |
| 2004 FY | 1.08 Million USD | 42.92% |
| 2004 Q2 | 768.95 Thousand USD | 22.32% |
| 2003 Q2 | 649.04 Thousand USD | 13.88% |
| 2003 FY | 760.52 Thousand USD | 475.16% |
| 2003 Q4 | 760.52 Thousand USD | 62.33% |
| 2003 Q3 | 468.5 Thousand USD | -27.82% |
| 2003 Q1 | 569.96 Thousand USD | 331.04% |
| 2002 Q3 | 40.57 Thousand USD | 367.92% |
| 2002 FY | 132.22 Thousand USD | -48.4% |
| 2002 Q4 | 132.22 Thousand USD | 225.9% |
| 2002 Q2 | 8671.00 USD | -90.2% |
| 2002 Q1 | 88.47 Thousand USD | -65.47% |
| 2001 Q2 | 165.51 Thousand USD | -6.19% |
| 2001 Q3 | 169.93 Thousand USD | 2.67% |
| 2001 Q4 | 256.23 Thousand USD | 50.79% |
| 2001 FY | 256.23 Thousand USD | 61.85% |
| 2001 Q1 | 176.44 Thousand USD | 11.45% |
| 2000 Q4 | 158.31 Thousand USD | -6.95% |
| 2000 Q3 | 170.13 Thousand USD | 3.1% |
| 2000 FY | 158.31 Thousand USD | 0.01% |
| 2000 Q1 | 192.81 Thousand USD | 0.0% |
| 2000 Q2 | 165.01 Thousand USD | -14.42% |
| 1999 FY | 158.3 Thousand USD | 17.21% |
| 1998 FY | 135.05 Thousand USD | -3.99% |
| 1997 FY | 140.67 Thousand USD | -17.55% |
| 1996 FY | 170.62 Thousand USD | -3.65% |
| 1995 FY | 177.08 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -21197.784% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 38.277% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 91.938% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -622.387% |
| Rebus Holdings, Inc. | 5.24 Million USD | -11.458% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 90.1% |
| Qrons Inc. | 1.48 Million USD | -292.461% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -376.477% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 92.202% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -12971.91% |
| Skye Bioscience, Inc. | 14.07 Million USD | 58.481% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 89.039% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 39.025% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1285.926% |
| SQZ Biotechnologies Company | 50.03 Million USD | 88.324% |
| Intellipharmaceutics International Inc. | 12 Million USD | 51.347% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -51.7% |
| Mesoblast Limited | 188.44 Million USD | 96.9% |
| Marizyme, Inc. | 26.67 Million USD | 78.098% |
| Genus plc | 485 Million USD | 98.795% |
| Pharming Group N.V. | 244.07 Million USD | 97.606% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -190.659% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -132.188% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -53.753% |
| ContraFect Corporation | 32.53 Million USD | 82.04% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -194.887% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -52.643% |
| IMV Inc. | 37.93 Million USD | 84.597% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 50.395% |
| MultiCell Technologies, Inc. | 1617.67 USD | -361075.085% |
| ONE Bio Corp. | 27.49 Million USD | 78.751% |
| Accustem Sciences Inc. | 1.07 Million USD | -441.365% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 92.453% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -176.238% |
| Q BioMed Inc. | 8.13 Million USD | 28.161% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 92.955% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -13.536% |
| Biomind Labs Inc. | 1.49 Million USD | -289.869% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 95.079% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 35.385% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 68.253% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -307.475% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -4011.771% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2805.1% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -1.685% |
| GB Sciences, Inc. | 5.41 Million USD | -7.846% |
| Alpha Cognition Inc. | 7.16 Million USD | 18.454% |
| HST Global, Inc. | 593.59 Thousand USD | -884.281% |
| CSL Limited | 18.62 Billion USD | 99.969% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -363.997% |
| Halberd Corporation | 728.71 Thousand USD | -701.766% |
| Enzolytics Inc. | 365.26 Million USD | 98.4% |
| Agentix Corp. | 2.51 Million USD | -132.722% |
| Resverlogix Corp. | 67.39 Million USD | 91.331% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -596.602% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.687% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -240.876% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 76.39% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 50.915% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -59.41% |
| AVAX Technologies, Inc. | 3.99 Million USD | -46.294% |
| Zenith Capital Corp. | 27.56 Thousand USD | -21092.72% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.559% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2348.155% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -56.458% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -758.156% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -115.464% |
| Kadimastem Ltd | 3.5 Million USD | -66.7% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -8629.581% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 88.376% |
| BioStem Technologies, Inc. | 15.9 Million USD | 63.265% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1157.291% |
| LadRx Corporation | 2.2 Million USD | -165.51% |
| Cell Source, Inc. | 15.8 Million USD | 63.037% |
| Regen BioPharma, Inc. | 5.45 Million USD | -7.054% |
| Regen BioPharma, Inc. | 5.45 Million USD | -7.054% |
| NovAccess Global Inc. | 7.86 Million USD | 25.673% |
| Affymax, Inc. | 8.87 Million USD | 34.138% |
| Itoco Inc. | 1.65 Million USD | -253.423% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -184.788% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 3.412% |
| Mobile Lads Corp. | 1.31 Million USD | -344.814% |
| CytoDyn Inc. | 127.89 Million USD | 95.432% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -13877.897% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -273.002% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 47.103% |
| SYBLEU INC | 681.41 Thousand USD | -757.427% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 4.249% |
| International Stem Cell Corporation | 5.27 Million USD | -10.719% |
| Bioxytran, Inc. | 3.24 Million USD | -79.801% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -833.611% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -26.542% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 85.748% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 73.759% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -188.469% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -6.656% |
| Neutra Corp. | 973.52 Thousand USD | -500.149% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 79.863% |
| PureTech Health plc | 125.58 Million USD | 95.348% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -55.508% |
| IXICO plc | 1.9 Million USD | -207.459% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 71.54% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 94.345% |
| CSL Limited | 18.62 Billion USD | 99.969% |
| Cellectis S.A. | 249.36 Million USD | 97.657% |